Benzinga··Globe NewswireMerck to Acquire Terns Pharmaceuticals for $6.7B to Bolster CML Portfolio
Merck acquires Terns Pharmaceuticals for $6.7 billion to gain TERN-701, a novel leukemia treatment, at 31% premium valuation.
MRKTERNacquisitionM&A
hematology
2 articlesBenzinga··Globe Newswire
GlobeNewswire Inc.··Researchandmarkets.ComPegasys Market Poised for Growth Despite DAA Competition and Tariff Headwinds
Pegasys market projected for growth via rising hepatitis B prevalence and indication expansion, though direct-acting antivirals and tariff pressures pose challenges. Asia-Pacific represents fastest-growing region.
PFERHHBYGRFSemerging marketsoncology